• How Smartwatches are Advancing Sleep Measurement

    Jan 20 | Clinical Research News | Artificial intelligence (AI) is reshaping how clinical researchers study sleep, which has been tested with either simple self-reporting sleep logs or cumbersome sleep studies that take place in a lab or clinic. A new AI-driven sleep-staging framework called BIDSleep was developed at the University of Massachusetts Amherst. More

  • Closing the Research Gap in Africa Through Decentralized Patient Engagement and Remote Trial Models

    Jan 16 | Clinical Research News | Africa remains one of the most important yet underleveraged regions in global drug development. The continent carries a substantial share of disease burden but contributes only a small fraction of clinical trial activity. This imbalance is not driven by scientific limitations or lack of patient interest. It reflects structural constraints that traditional site centric trial models have failed to overcome at scale. More

  • A Stronger, More Disciplined Future for Emerging Biopharma

    Jan 13 | Clinical Research News | With the close of 2025 came the end of a prolonged biotech winter marked by reduced funding, massive job cuts, investor skepticism, and initial public offering slowdown. The experience, while painful, helped mature the biopharma industry with operational discipline and a new playbook for how to make the case with investors moving forward. More

  • New In-Ear EEG Platform Opens Door to Real-World Neurological Data Collection

    Jan 12 | Clinical Research News | A newly FDA-cleared in-ear electroencephalogram (EEG) device could significantly alter how neurological conditions are studied, screened, and monitored outside traditional clinical settings. Paris-based Naox Technologies announced at CES 2026 in Las Vegas that its medical-grade Naox Link system has received U.S. Food and Drug Administration 510(k) clearance. More

  • The Scope of Things: Raising the Bar for Evidence Generation in Clinical Research

    Jan 08 | Clinical Research News | As clinical research faces mounting pressure to generate real-world evidence faster and more efficiently, non-interventional studies may be a useful tool to achieve this. Yet, they have been historically underutilized. More

  • Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites

    Jan 06 | Clinical Research News | To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage. More

  • Top Stories of 2025: AI in Clinical Research, Pharmacy Recruitment, Pragmatic Trials

    Dec 29 | Clinical Research News | In clinical research, AI was the hottest topic this year, with the Food & Drug Administration, big pharma, and researchers exploring ways generative AI can help with drug discovery, the clinical trials process, and the regulatory landscape. But clinical trials are still a personal venture, and other stories topped the list highlighting the person-to-person interaction necessary for trial success. More

  • Follow the Money: AL Amyloidosis Trial, Cancer Medicine Programs, Focal Refractory Epilepsy Treatment

    Dec 23 | Clinical Research News | Protego Biopharma will advance their lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis; BlossomHill will expand their cancer medicine programs; EpilepsyGTx will advance its lead program EPY201 through Phase 1/2a clinical trials for focal refractory epilepsy; and more. More

  • New Members at NORD, Pangea, AstraZeneca Collaboration, Predicting Human Toxicity

    Dec 22 | Clinical Research News | The National Organization for Rare Disorders (NORD) adds seven new members its national NORD Rare Disease Centers of Excellence Network; Pangaea announces a multi‑year strategic collaboration with AstraZeneca; Sanford Burnham Prebys Medical Discovery Institute plan to develop computational models to predict human toxicity; and more. More

  • Clinical Trials Evolve: Mixed FSP/FSO Models Add Agility and Expertise

    Dec 19 | Clinical Research News | For every day of delay in a clinical trial, sponsors lose $500,000 in prescription drug sales and incur $40,000 in direct clinical trial costs, according to the Tufts Center for the Study of Drug Development. These numbers show why speed and control matter more than ever, as drug development continues getting more complex and expensive. More
View more articles
 
DXX-Industry-spotlight
SOT

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News Senior writer Deborah Borfitz welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.

Read More